The Impact of Varying Numbers of Quadrivalent Human Papillomavirus Vaccine Doses on Anogenital Warts in the United States: A Database Study

Burak Zeybek, Yu Li Lin, Yong Fang Kuo, Ana Rodriguez

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective The aim of the study was to investigate the effects of 3 or less quadrivalent human papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the United States. Materials and Methods We conducted a retrospective database study that included males and females aged 9 to 26 years who received varying numbers of vaccine doses between 2006 and 2015. The primary outcome was the incidence of anogenital warts starting 3 months after the last dose of the HPV vaccine. Proportional hazard regression models were used to examine the association between the number of HPV vaccine doses and the incidence of anogenital warts. The Kaplan-Meier method was used to estimate the proportion of subjects. Results A total of 440,532 females and 133,394 males were included in the study. We found a significant 2-way interaction (p <.0001) between the number of doses and age. For the group between 15 and 19 years of age, the hazard ratio of anogenital warts for the 3-dose vaccine was 0.58 (95% CI = 0.49-0.70), whereas it was 0.65 (95% CI = 0.49-0.85) and 0.67 (95% CI = 0.51-0.89) for the 1- and 2-dose groups, respectively. Conclusions Our findings showed that 1, 2, and 3 doses of the quadrivalent HPV vaccine were similarly effective against anogenital warts in 15- to 19-year-old adolescents, irrespective of sex.

Original languageEnglish (US)
Pages (from-to)189-194
Number of pages6
JournalJournal of Lower Genital Tract Disease
Volume22
Issue number3
DOIs
StatePublished - Jul 1 2018

Fingerprint

Papillomavirus Vaccines
Warts
Databases
Vaccines
Incidence
Proportional Hazards Models
Retrospective Studies

Keywords

  • 2 doses
  • 3 doses
  • anogenital warts
  • quadrivalent HPV vaccine
  • single dose
  • vaccine effectiveness

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

@article{2356e8910e8c4d88b3e10a850e71ac5f,
title = "The Impact of Varying Numbers of Quadrivalent Human Papillomavirus Vaccine Doses on Anogenital Warts in the United States: A Database Study",
abstract = "Objective The aim of the study was to investigate the effects of 3 or less quadrivalent human papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the United States. Materials and Methods We conducted a retrospective database study that included males and females aged 9 to 26 years who received varying numbers of vaccine doses between 2006 and 2015. The primary outcome was the incidence of anogenital warts starting 3 months after the last dose of the HPV vaccine. Proportional hazard regression models were used to examine the association between the number of HPV vaccine doses and the incidence of anogenital warts. The Kaplan-Meier method was used to estimate the proportion of subjects. Results A total of 440,532 females and 133,394 males were included in the study. We found a significant 2-way interaction (p <.0001) between the number of doses and age. For the group between 15 and 19 years of age, the hazard ratio of anogenital warts for the 3-dose vaccine was 0.58 (95{\%} CI = 0.49-0.70), whereas it was 0.65 (95{\%} CI = 0.49-0.85) and 0.67 (95{\%} CI = 0.51-0.89) for the 1- and 2-dose groups, respectively. Conclusions Our findings showed that 1, 2, and 3 doses of the quadrivalent HPV vaccine were similarly effective against anogenital warts in 15- to 19-year-old adolescents, irrespective of sex.",
keywords = "2 doses, 3 doses, anogenital warts, quadrivalent HPV vaccine, single dose, vaccine effectiveness",
author = "Burak Zeybek and Lin, {Yu Li} and Kuo, {Yong Fang} and Ana Rodriguez",
year = "2018",
month = "7",
day = "1",
doi = "10.1097/LGT.0000000000000401",
language = "English (US)",
volume = "22",
pages = "189--194",
journal = "Journal of Lower Genital Tract Disease",
issn = "1089-2591",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The Impact of Varying Numbers of Quadrivalent Human Papillomavirus Vaccine Doses on Anogenital Warts in the United States

T2 - A Database Study

AU - Zeybek, Burak

AU - Lin, Yu Li

AU - Kuo, Yong Fang

AU - Rodriguez, Ana

PY - 2018/7/1

Y1 - 2018/7/1

N2 - Objective The aim of the study was to investigate the effects of 3 or less quadrivalent human papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the United States. Materials and Methods We conducted a retrospective database study that included males and females aged 9 to 26 years who received varying numbers of vaccine doses between 2006 and 2015. The primary outcome was the incidence of anogenital warts starting 3 months after the last dose of the HPV vaccine. Proportional hazard regression models were used to examine the association between the number of HPV vaccine doses and the incidence of anogenital warts. The Kaplan-Meier method was used to estimate the proportion of subjects. Results A total of 440,532 females and 133,394 males were included in the study. We found a significant 2-way interaction (p <.0001) between the number of doses and age. For the group between 15 and 19 years of age, the hazard ratio of anogenital warts for the 3-dose vaccine was 0.58 (95% CI = 0.49-0.70), whereas it was 0.65 (95% CI = 0.49-0.85) and 0.67 (95% CI = 0.51-0.89) for the 1- and 2-dose groups, respectively. Conclusions Our findings showed that 1, 2, and 3 doses of the quadrivalent HPV vaccine were similarly effective against anogenital warts in 15- to 19-year-old adolescents, irrespective of sex.

AB - Objective The aim of the study was to investigate the effects of 3 or less quadrivalent human papillomavirus (HPV) vaccine doses on anogenital warts in both males and females in the United States. Materials and Methods We conducted a retrospective database study that included males and females aged 9 to 26 years who received varying numbers of vaccine doses between 2006 and 2015. The primary outcome was the incidence of anogenital warts starting 3 months after the last dose of the HPV vaccine. Proportional hazard regression models were used to examine the association between the number of HPV vaccine doses and the incidence of anogenital warts. The Kaplan-Meier method was used to estimate the proportion of subjects. Results A total of 440,532 females and 133,394 males were included in the study. We found a significant 2-way interaction (p <.0001) between the number of doses and age. For the group between 15 and 19 years of age, the hazard ratio of anogenital warts for the 3-dose vaccine was 0.58 (95% CI = 0.49-0.70), whereas it was 0.65 (95% CI = 0.49-0.85) and 0.67 (95% CI = 0.51-0.89) for the 1- and 2-dose groups, respectively. Conclusions Our findings showed that 1, 2, and 3 doses of the quadrivalent HPV vaccine were similarly effective against anogenital warts in 15- to 19-year-old adolescents, irrespective of sex.

KW - 2 doses

KW - 3 doses

KW - anogenital warts

KW - quadrivalent HPV vaccine

KW - single dose

KW - vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85048928867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048928867&partnerID=8YFLogxK

U2 - 10.1097/LGT.0000000000000401

DO - 10.1097/LGT.0000000000000401

M3 - Article

C2 - 29762430

AN - SCOPUS:85048928867

VL - 22

SP - 189

EP - 194

JO - Journal of Lower Genital Tract Disease

JF - Journal of Lower Genital Tract Disease

SN - 1089-2591

IS - 3

ER -